---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-006284"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T20:55:05.977691+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma receives Nasdaq deficiency notice for bid price below $1.00 per share

## Summary
- Received Nasdaq deficiency letter on Feb 22, 2023; stock closed below $1.00 for 30 consecutive business days.
- Has 180 calendar days, until August 21, 2023, to regain compliance by closing at $1.00+ for 10 consecutive business days.
- May qualify for a second 180-day period if it meets other listing standards and provides written notice.
- Company intends to monitor bid price and consider available options to cure the deficiency.

## SEC filing metadata
- accession: 0001493152-23-006284
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315223006284/0001493152-23-006284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315223006284/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-006284
- JSON: https://secwatch.observer/filing/0001493152-23-006284.json
- Plain text: https://secwatch.observer/filing/0001493152-23-006284.txt

## Key facts
- Listing & Compliance Notices
  GT Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: February 22, 2023, GT Biopharma, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315223006284/0001493152-23-006284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.